Ars Pharmaceuticals, INC Form 4 insider transactions

RA Capital Management and its affiliated funds, along with directors Peter Kolchinsky and Rajeev Shah, have reported the grant of 30,000 stock options to Dr. Peter Kolchinsky by ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. Director Rajeev Dadoo was granted 30,000 stock options with an exercise price of $17.26, vesting by June 2026.

ARS Pharmaceuticals, Inc. Director Pratik Shah was granted 30,000 stock options with an exercise price of $17.26, vesting by June 25, 2026, or the 2026 annual meeting.

ARS Pharmaceuticals, Inc. Director Michael Kelly was granted 30,000 stock options with an exercise price of $17.26, vesting by June 2026.

ARS Pharmaceuticals, Inc. Director Saqib Islam was granted 30,000 stock options with an exercise price of $17.26, vesting by June 2026.

ARS Pharmaceuticals' Chief Commercial Officer, Eric Karas, exercised stock options and subsequently sold 15,000 shares of common stock for a significant profit under a pre-arranged Rule 10b5-1 trading plan.

Kathleen Scott, CFO of ARS Pharmaceuticals, exercised stock options and sold 50,000 shares of common stock on May 20, 2025.

Alexander Fitzpatrick, Chief Legal Officer of ARS Pharmaceuticals, reports the acquisition and disposal of common stock and stock options.

Director Brent Saunders exercised stock options and sold 120,000 shares of ARS Pharmaceuticals, Inc. on May 20, 2025.

Director Laura Shawver exercised stock options and sold shares of ARS Pharmaceuticals, Inc. on April 7, 2025, according to a Form 4 filing with the SEC.

Chief Commercial Officer Eric Karas exercised stock options and sold shares of ARS Pharmaceuticals under a pre-arranged trading plan.

Director Laura Shawver of ARS Pharmaceuticals, Inc. exercised stock options and sold shares of common stock on March 5th and 6th, 2025, according to a Form 4 filing with the SEC.

Director Laura Shawver exercised stock options and sold shares of ARS Pharmaceuticals, Inc. on February 3, 2025, according to a Form 4 filing with the SEC.

Laura Shawver, a director at ARS Pharmaceuticals, sold 50,000 shares and exercised options for 50,000 shares on January 6, 2025.

Alexander A. Fitzpatrick, Chief Legal Officer of ARS Pharmaceuticals, acquired stock options for 152,300 shares on January 2, 2025, according to a Form 4 filing.

Brian Dorsey, Chief Operating Officer of ARS Pharmaceuticals, acquired stock options for 261,900 shares on January 2, 2025, according to a Form 4 filing.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, reports acquisition of stock options.

Richard E. Lowenthal, CEO of ARS Pharmaceuticals, acquired a total of 1,029,500 stock options on January 2, 2025, both directly and indirectly through his spouse.

Justin Chakma, Chief Business Officer of ARS Pharmaceuticals, acquired stock options for 274,100 shares on January 2, 2025, according to a recent SEC filing.

Kathleen D. Scott, CFO of ARS Pharmaceuticals, acquired stock options for 176,700 shares on January 2, 2025, according to a Form 4 filing.

Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals, acquired stock options for 152,300 shares on January 2, 2025, vesting monthly over four years.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, executed sales of common stock on December 17, 2024, according to a recent SEC filing.

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on December 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

ARS Pharmaceuticals' Chief Business Officer, Justin Chakma, exercised stock options and sold shares on December 12th and 13th, 2024.

Brian Dorsey, Chief Operating Officer of ARS Pharmaceuticals, exercised stock options and sold shares on December 11th and 12th, 2024.

An ARS Pharmaceuticals executive, Justin Chakma, executed a series of transactions involving the company's stock, including selling shares and exercising options.

ARS Pharmaceuticals' Chief Medical Officer, Sarina Tanimoto, sold 100,000 shares of common stock through trusts under a pre-arranged 10b5-1 trading plan.

ARS Pharmaceuticals CEO Richard E. Lowenthal sold 150,000 shares of common stock through trusts under a pre-arranged trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, reported exercising stock options and acquiring shares, increasing her direct and indirect holdings.

ARS Pharmaceuticals CEO Richard E. Lowenthal exercised stock options and adjusted his holdings, including those held indirectly through trusts and his spouse.